Attuali Prospettive Terapeutiche Nel Trattamento Delle Complicanze Emorragiche Nei Pazienti Uremici in Trattamento Dialitico: Ruolo Della Terapia Con Estrogeni Coniugati e Loro Effetti Sulle Interazioni Piastrine-Endotelio Mediati Da Riespressione Delle Integrine Di Superficie Sulla Membrana Piastrinica
Restricted accessResearch articleFirst published online October, 1997
Attuali Prospettive Terapeutiche Nel Trattamento Delle Complicanze Emorragiche Nei Pazienti Uremici in Trattamento Dialitico: Ruolo Della Terapia Con Estrogeni Coniugati e Loro Effetti Sulle Interazioni Piastrine-Endotelio Mediati Da Riespressione Delle Integrine Di Superficie Sulla Membrana Piastrinica
WatsonA.J., GimenezL.F.The bleeding diathesis of uremia. Semin Dial1991; 4: 86–93.
2.
Di MinnoG., MartinezJ., McKeanM.L., DeLa RosaJ., BurkeJ.F., MurphyS.Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis. Am J Med1985; 79: 552–9.
3.
LivioE., BenigniA., RemuzziG.Coagulation abnormalities in uremia. Semin Nephrol1985; 5: 82–90.
4.
EscolarG., CasesA., BastidaE.Uraemic platelets have a functional defect affecting the interaction of von Willebrand Factor with glycoprotein IIb/IIIa:Blood1990; 76: 1336–40.
5.
SloandE.M., SloandJ.A., ProdouzK.Reduction of platelet glycoprotein Ib in uremia. Br J Haematol1991; 77: 375–81.
6.
LianiM., SalvatiF., GolatoM., TrescaE.Platelet glycoproteins GPIb and GPIIb/IIIa abnormalities in uremia. Nephron1996; 72: 716.
7.
GawazM.P., DobosG., SpathM.Impaired function of platelet membrane glycoprotein IIb/IIIa in end stage renal disease. J Am Soc Nephrol1994; 5: 36–46.
8.
BenigniA., BoccardoP., GalbuseraM.Reversible activation defect of the platelet glycoprotein IIb/IIIa complex in patients with uremia. Am J Kidney Dis1993; 22: 668–76.
9.
The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl. J Med1994; 330: 956–61.
10.
TchengJ.E.Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT-II, RESTORE and EPILOG trials into perspective. Am J Cardiol1996; 78(Suppl 3A): 35–40.
11.
The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina. The CAPTURE Study. Lancet1997; 349: 1429–35.
12.
The Impact II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet1997; 349: 1422–8.
13.
KereiakesD.J., RunyonJ.P., KleimanN.S.Differential dose-response to oral xemilofiban after antecedent intra venous abciximab. Administration for complex coronary intervention. Circulation1996; 94: 906–10.
14.
VerheugtF.W.In search of a superaspirin for the heart. Lancet1997; 349: 1409–10.
15.
LianiM., SalvatiF., TrescaE.Arteriovenous fistula obstruction and expression of platelet receptors for von Willebrand Factor and for fibrinogen (glycoproteins GPIb and GPIIb/IIIa) in hemodialysis patients. Int J Artif Organs1996; 19: 451–4.
16.
LianiM., SalvatiF., TrescaE.Bleeding diathesis in uremic patients treated with peritoneal dialysis: role of glycoproteins GPIb and GPIIb/IIIa abnormalities. Nephron1996; 74: 234.
17.
SloandJ.A.Long term therapy for uremic bleeding. Int J Artif Organs1996; 19: 439–40.
18.
LianiM., SalvatiF., NubileG., TrescaE., VelussiC., MidrioM.Von Willebrand Factor and rise in ristocetin co-factor with erythropoietin. Lancet1993; 341: 1221.
19.
JansonP.A., JubelilerS.J., WeinstenM.S., DeykinD.Treatment of bleeding tendency in uremia with cryoprecipitate. N Engl J Med1980; 303: 1318–22.
20.
SloandE.M., KesslerC.M., SloandJ.A.DDAVP corrects the platelet dysfunction produced by cardiopulmonary by-pass, hemodialysis, and prolonged storage: Re-expression of GPIb on the platelet membrane.New York: Plenum Press, Desmopressin in Bleeding Dis1993; 147–54.
21.
ViganóG., GaspariF., LocatelliM., PusineriF., BonatiM., RemuzziG.Dose-effect and pharmacokinetics of estrogens given to correct bleeding time in uremia. Kidney Int1988; 34: 853–8.
22.
ZoyaC., NorisM., CornaD.L-Arginine, the precursor of nitric oxide, abolishes the effect of estrogens on bleeding time in experimental uremia. Lab Invest1991; 65: 479–83.
23.
HoffmannJJML, JanssenW.C.M.Interactions between thrombolytic agents and platelets: effects of plasmine on platelet glycoproteins Ib and IIb/IIIa. Thrombosis Research1992; 67: 711–9.
24.
LianiM., TrescaE., NubileG., SalvatiF., TrollietP., CahenR.Effects of dietary manipulation with Fish-Oil on platelet receptors for von Willebrand Factor and Fibrinogen in Patients with end-stage renal failure. Nephron1995; 69: 170.
25.
SalvatiF., LianiM., GolatoM.Long term therapy for uremic bleeding: effects of conjugate estrogens on the expression of platelet surface receptors for von Willebrand Factor and fibrinogen (GPIb and GPIIb/IIIa glycoproteins). Int J Artif Organs1997; 20: 184–5.
